Iteos Therapeutics Inc - Asset Resilience Ratio
Iteos Therapeutics Inc (ITOS) has an Asset Resilience Ratio of 49.37% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ITOS current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2024)
This chart shows how Iteos Therapeutics Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Iteos Therapeutics Inc.
Liquid Assets Composition Over Time
This chart breaks down Iteos Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Iteos Therapeutics Inc long-term investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $307.61 Million | 49.37% |
| Total Liquid Assets | $307.61 Million | 49.37% |
Asset Resilience Insights
- Very High Liquidity: Iteos Therapeutics Inc maintains exceptional liquid asset reserves at 49.37% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Iteos Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Iteos Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Iteos Therapeutics Inc (2021–2024)
The table below shows the annual Asset Resilience Ratio data for Iteos Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 51.31% | $352.52 Million | $686.98 Million | +9.26pp |
| 2023-12-31 | 42.05% | $280.74 Million | $667.59 Million | -1.44pp |
| 2022-12-31 | 43.49% | $328.36 Million | $754.99 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $884.71 Million | -- |
About Iteos Therapeutics Inc
iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), as well as engages the Fc gamma receptor to activate dendritic cells, natural killer cells, T lym… Read more